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SUMMARY
A 15-month survey of 412 bloodstream yeast isolates from 54 Belgian hospitals was undertaken.
Candida albicans was the most common species (47.3%) followed by C. glabrata (25.7%),
C. parapsilosis (8.0%), C. tropicalis (6.8%) and Saccharomyces cerevisiae (5.1%). Common
predisposing factors were antibacterial therapy (45%), hospitalization in intensive care units
(34%), presence of in-dwelling catheters (32%), underlying cancer (23%) and major surgery
(11%). Most patients had more than one predisposing factor. Fluconazole alone or in
combination with another antifungal agent was the treatment of choice for 86.6% of the cases.
Susceptibility testing revealed that 93.5% were susceptible to amphotericin B, 39.6% to
itraconazole, 42.8% to ﬂuconazole and 87% to voriconazole. Resistance to azoles was more
common among C. glabrata isolates.
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The use of aggressive chemotherapeutic and immuno-
suppressive agents as well as broad-spectrum anti-
microbials has created a large population of patients
who are at increased risk of acquiring infections from
fungal organisms, especially Candida spp. C. albicans
accounts for over the half of all cases of invasive
candidiasis but C. glabrata has emerged as the second
most common cause and several other yeast species
are also increasing in frequency [1, 2]. The ﬁrst com-
prehensive survey of fungal infection in Belgium was
carried out in 2002 [3] and the species of yeast, poten-
tial risk factors and susceptibilities to antifungal
agents were deﬁned for 211 isolates from 207 patients
in 28 hospitals. We repeated the survey over a 15-
month period and involved twice the number of
patients and hospital centres to assess whether the
earlier ﬁndings hold true.
Fifty-ﬁve centres contributed isolates to the study
between June 2005 and September 2006. Isolates were
subcultured on Sabouraud’s agar for 24 h at 35 xC
and identiﬁed by standard methods [4, 5].
Susceptibility testing was performed and interpreted
as described in the Clinical Laboratory Standards
Institute (CLSI) breakpoints guidelines [6]. Antifungal
drugs tested were amphotericin B, itraconazole, ﬂuco-
nazole and voriconazole. As oﬃcial CLSI interpret-
ative breakpoints are not available for amphotericin
B, the breakpoints recommended by Pfaller & Die-
kema were used [2]. The amount of glucose in the
RPMI medium was doubled to 2% to support opti-
mal growth of isolates [7].
A total of 412 yeast isolates was collected from 402
patients ; 10 patients had a double yeast infection. As
found in the 2002 survey [3], the majority of patients
(54.8%) were male and aged>65 years of age (60%),
a ﬁnding consistent with the literature [8, 9] and the
same ﬁve most common risk factors in 2002 were also
associated, i.e. antimicrobial therapy (45%), stay in
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intensive care units (34%), the presence of in-dwelling
catheters (32%), underlying cancer (23%), and major
surgery (11%). Most patients had more than one
predisposing factor.
Data for 292 patients showed that ﬂuconazole alone
or in combination with another antifungal agent was
the treatment of choice for 253 patients (86.6%)
Fluconazole monotherapy was prescribed for 231
patients (79.1%); echinocandins (caspofungin or
micafungin) were used singly for 21 patients (7.2%);
voriconazole, amphotericin B and itraconazole singly
for six, four and three patients, respectively. One
patient received amphotericin B and 5-ﬂuorocytosine
and 26 (8.9%) received diﬀerent sequential mono-
therapies. An increase in the use of echinocandins
reﬂects practice in other Belgian centres [10].
Table 1 shows that of the 412 isolates, 195
(47.3%) were C. albicans ; the other most common
species were C. glabrata (25.7%), C. parapsilosis
(8.0%) and C. tropicalis (6.8%). The incidence of
C. albicans and C. parapsilosis was lower than in 2002
(55% and 13% in 2002, respectively). C. glabrata and
C. tropicalis increased (22% and 2.8% in 2002, re-
spectively). It is noteworthy that C. glabrata infec-
tions are more commonly associated with the elderly
and this may explain the increase observed in the
present study which involved more elderly patients
than the 2002 survey. By contrast C. parapsilosis is
generally more frequent in children and the low
number of isolates recovered in this group probably
reﬂects the small number of patients (4.4%) aged
<15 years [8]. There was about a threefold increase in
the frequency of Saccharomyces cerevisiae and 19/21
isolates gave a proﬁle of the variety boulardii which is
widely used in probiotics, although biotherapy was
only cited three times as a risk factor. In the 10
patients with double yeast infections, C. albicans was
associated with C. glabrata in ﬁve, with C. parapsilosis
in two, and with S. cerevisiae in a single patient.
C. glabrata was isolated with C. parapsilosis and
C. tropicalis in separate patients.
The antimicrobial susceptibility of the 217 non-
C. albicans isolates is shown in Table 2. Compared
with the results obtained using the Sensititre YeastOne
commercial system (Trek Diagnostic Systems, East
Grinstead, UK) in 2002, resistance increased to
amphotericin B (6.4% vs. 1% in 2002), itraconazole
(30.4% vs. 7%) and ﬂuconazole (20.7% vs. 3%).
Dose-dependent susceptibility was exhibited by
29.9% and 36.4% of isolates to itraconazole and ﬂu-
conazole, respectively, and this represented an increase
from the 2002 survey. Indeed, only 39.6% of isolates
were fully susceptible to itraconazole and 42.8% to
ﬂuconazole (69% and 82% in 2002, respectively).
C. glabrata isolates were mostly responsible for the
decrease in susceptibility to these latter agents which
was also observed by Lagrou et al. [10] using the
Sensititre YeastOne commercial system. Resistance
to ﬂuconazole was observed in all but three of the
C. krusei isolates, a frequently intrinsically resistant
species [9]. Voriconazole showed excellent activity
with 87.1% of isolates inhibited byf1 ml/ml. Eleven
out of the 15 resistant isolates were C. glabrata and 13
(11 C. glabrata and two Rhodotorula mucilaginosa)
showed cross-resistance to the other azoles tested.
Susceptibility to voriconazole was not tested for in the
2002 survey but an earlier study from this laboratory
showed excellent potency and broad spectrum activity
against non-C. albicans isolates [11] ; this ﬁnding is
conﬁrmed here.
In conclusion, the percentage of bloodstream in-
fections due to C. albicans isolates is decreasing in
Belgium, probably as a consequence of the use of
azoles selecting for more resistant non-C. albicans
species, of which C. glabrata remains the most diﬃ-
cult to treat eﬀectively.
APPENDIX
Participants from Belgian institutes contributing
isolates
Academisch Ziekenhuis Vlaamse Universiteit,
Brussels (S. Lauwers, D. Pie´rart) ; Algemeen Zieken-
huis Damiaan, Oostende (G. Alliet) ; Algemeen
Table 1. Yeast species isolated from blood cultures
Species Isolates, n (%)
Candida albicans 195 (47.3)
Candida glabrata 106 (25.7)
Candida parapsilosis 33 (8.0)
Candida tropicalis 28 (6.8)
Saccharomyces cerevisisae 21 (5.1)
Candida krusei 16 (3.9)
Pichia anomala 3 (0.7)
Cryptococcus neoformans 3 (0.7)
Rhodotorula mucilaginosa 2 (0.5)
Candida inconspicua 1 (0.2)
Candida famata 1 (0.2)
Kluyveromyces marxianus 1 (0.2)
Cryptococcus laurentii 1 (0.2)
Geotrichum candidum 1 (0.2)
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Ziekenhuis Groeninge, Kortrijk (J. Colaert) ; Alge-
meenZiekenhuisMiddelheim,Antwerpen (A.Mertens);
Algemeen Ziekenhuis Jan Palﬁjn, Merksem (M.
Mollemans) ; Algemeen Ziekenhuis Klina, Braaschaat
(G. Eykens) ; Algemeen Ziekenhuis Sint Augustinus,
Wilrijk (J. Van Schaeren) ; Algemeen Ziekenhuis Sint
Dimpna, Geel (G. de Muˆelenaere) ; Algemeen Zie-
kenhuis St Elisabeth, Herentals (L. De Wolf) ;
Algemeen Ziekenhuis St Jan, Brugge (E. Nulens) ; Al-
gemeen Ziekenhuis Sint Lucas, Gent (A. M. Van Den
Abeele) ; Algemeen Ziekenhuis Sint Maarten, Meche-
len (A. Lemmens, K. Vermaelen); Algemeen Zie-
kenhuis M. Middelares-St Jozef, Gent (J. Dierick) ;
Algemeen Ziekenhuis Stuivenberg, Antwerpen (K.
Camps); Clinique Edith Cavell, Brussels (Y. De
Gheldre) ; Clinique de l‘Europe-site : Sainte-Elisabeth,
Brussels (D. Allemeersch) ; Clinique Ge´ne´rale Saint-
Jean, Brussels (B. Mulongo, M. Wegge) ; Clinique Jo-
seph Bracops, Brussels (A. I. de Moreau) ; Clinique
Notre-Dame de Graˆce, Gosselies (N. Fonteyn, B.
Gualtieri) ; Clinique Notre-Dame, Tournai (P. Struy-
ven) ; Clinique du Parc Le´opold, Brussels (D. Bosson,
C. Tilmant); Clinique Sainte-Elisabeth, Namur (P.
Gavage); Clinique Saint-Luc, Bouge (K. Laﬃneur) ;
Clinique Sud Luxembourg, Arlon (P. Goﬃnet) ; Clin-
iques Universitaires St Pierre, Ottignies (J. Wautelet) ;
Cliniques Universitaires Saint-Luc, Brussels (J. Gigi) ;
Centre Hospitalier Notre-Dame et Reine Fabiola,
Charleroi (N. Thys) ; Centre Hospitalier Re´gional,
Huy (C. Sion); Centre Hospitalier Re´gional, Namur
(N. Thys) ; Centre Hospitalier Universitaire Brug-
mann, Brussels (G. Mascart) ; Centre Hospitalier
Universitaire Mont-Godinne, Yvoir (Y. Glupszyns-
ki) ; Centre Hospitalier Universitaire Tivoli, La Lou-
vie`re (C. Potvliege) ; Centre Hospitalier Universitaire
Andre´ Ve´sale, Montigny-le-Tilleul (D. Govaerts) ;
Dodoenziekenhuis, Mechelen (A. Lemmens); Heilig
Hart Ziekenhuis, Lier (W. Laﬀut) ; Heilig Hart Zie-
kenhuis, Mol (P. Verbeeck) ; Heilig Hart Ziekenhuis,
Roeselaere (I. Surmont, A. Verlinde) ; Henri Serruys
Ziekenhuis, Oostende (M. Van Kerkhove); Hoˆpital
Ambroise Pare´, Mons (M. Vatlet) ; Hoˆpital Saint-
Joseph, Charleroi (M. Fossion) ; Hoˆpital Erasme,
Universite´ libre, Brussels (M. J. Struelens, H. Villalo-
bos) ; Hoˆpital de Jolimont, Haine-Saint-Paul (F.
Meunier) ; Hoˆpital Militaire Reine Astrid, Brussels
(M. Pauwels) ; Onze Lieve Vrouwziekenhuis Aalst (A.
Boel) ; Onze Lieve Vrouw van Lourdes, Waregem (A.
Vuye) ; Sint Andriesziekenhuis, Tielt (C. Verdonckt) ;
Sint Augustinuskliniek, Veurne (A. Verhaeghe); Sint
Elisabethziekenhuis, Geel (T. Van Thienen); Stedelijk
Ziekenhuis, Roeselaere (R. De Smedt); Universitair
Ziekenhuis, Antwerpen (G. Ieven) ; Universitair Zie-
kenhuis, Gent (G. Claeys; G. Verschraegen) ; Virga
Table 2. Susceptibilities of 217 non-C. albicans yeast isolates from blood cultures to antifungals
Species
No. of
isolates
Amphotericin B Itraconazole Fluconazole Voriconazole
S SDD R S SDD R S SDD R S SDD R
Candida glabrata 106 103 — 3 7 42 57 19 58 29 83 12 11
Candida parapsilosis 33 31 — 2 29 4 0 33 0 0 33 0 0
Candida tropicalis 28 26 — 2 22 4 2 26 2 0 25 1 2
Saccharomyces cerevisiae 21 21 — 0 13 6 2 7 14 0 21 0 0
Candida krusei 16 10 — 6 7 6 3 0 3 13 16 0 0
Pichia anomala 3 3 — 0 3 0 0 2 1 0 3 0 0
Cryptococcus neoformans 3 3 — 0 2 1 0 3 0 0 3 0 0
Rhodotorula mucilaginosa 2 2 — 0 0 0 2 0 0 2 0 0 2
Candida inconspicua 1 1 — 0 1 0 0 1 0 0 1 0 0
Candida famata 1 1 — 0 0 1 0 0 1 0 1 0 0
Kluyveromyces marxianus 1 1 — 0 1 0 0 1 0 0 1 0 0
Cryptococcus laurentii 1 1 — 0 1 0 0 1 0 0 1 0 0
Geotrichum candidum 1 0 — 1 0 1 0 0 0 1 1 0 0
Total 217 203 — 14 86 65 66 93 79 45 189 13 15
S, Susceptible ; SDD, susceptible dose-dependent; R, resistant.
Amphotericin B (S: MICf1 mg/ml; SDD: not relevant; R: MICo2 mg/ml).
Itraconazole (S: MICf0.125 mg/ml; SDD: MIC between 0.25 and 0.5 mg/ml; R: MICo1 mg/ml).
Fluconazole (S: MICf8 mg/ml; SDD: MIC between 16 and 32 mg/ml; R: MICo64 mg/ml).
Voriconazole (S: MICf1 mg/ml; SDD: MIC=2 mg/ml, R: MICo4 mg/ml).
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Jesse Ziekenhuis, Hasselt (R. Cartuyvels, K. Mager-
man); J. Yperman Ziekenhuis, Ieper (P. Vandecan-
delaere) ; ZOL Campus Sint Jan, Genk (G. Coppens).
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